Vilitra is associated with vardenafil products in Centurion Laboratories’ India-market catalog. That is meaningful evidence of a company-linked product family, but the catalog is not a clean verified register of every variant: several entries show conflicts between headings, brand fields and strength rows. Those conflicts are central to responsible interpretation of Vilitra search results.
For example, Centurion’s list includes Vilitra 10 mg and 20 mg tablet descriptions as well as entries advertised at higher strengths. However, a listing headed as a particular higher-strength Vilitra presentation can show a different strength in the details, while a Vilitra-titled card can display another brand in its brand field. These are reasons to withhold definitive claims about a specific SKU until its original documentation is checked.
This guide focuses on Vilitra product evidence rather than generic clinical instructions or seller referrals. The India-market directory compares brands, and U.S.-approved generic vardenafil explains the distinct U.S. regulatory product category.
Centurion Laboratories has a public vardenafil product category in which Vilitra appears in item titles, formulation descriptions and some brand fields. This supports reporting an association between Centurion and a Vilitra-marketed family, but does not authenticate all goods advertised by third-party distributors.
The company may describe itself as manufacturer or supplier for specific entries. Before stating that a given finished tablet or batch was made at a defined facility, the actual package, national product record or authenticated manufacturer documentation should identify the responsible party. Avoid collapsing marketer, exporter and manufacturer into one unqualified role.
The table records documented *claims* rather than treating each entry as a verified medicinal product. Inconsistent source fields are not corrected by guessing which number was intended; a contradiction remains a contradiction until it can be resolved from primary product evidence.
In particular, a marketing heading is not an appropriate dose recommendation. Higher strengths appearing in foreign listings are not standard U.S. film-coated vardenafil tablet strengths.
| Company-listing example | Reported evidence | Editorial interpretation |
|---|---|---|
| Vilitra 10 mg tablets | Centurion catalog lists a 10 mg Vilitra entry | Company-linked tablet claim; verify original packaging |
| Vilitra 20 mg tablets | 20 mg listing appears under the family | Company-linked claim; some nearby fields show other brand names |
| Higher-strength Vilitra names | Listings include 40/60/80 mg terminology | Outside typical U.S. labeled tablet strengths; verify exact SKU |
| “Vilitra vardenafil 60 mg” card | A detail field also reports 40 mg | Internal contradiction: do not assert one strength as verified |
| Vilitra-titled 20 mg card | Brand field may display Valetra | Product-title and brand mismatch requires review |
| “Professional” presentation | Marketing mentions a professional form | Composition and dosage form require independent evidence |
| Super Vilitra tablet | Centurion-linked listing names vardenafil plus dapoxetine | Strength fields conflict; not ordinary vardenafil |
A mislabeled medicine strength is a potentially important clinical issue. Even when a web-catalog error is only a copywriting mistake, it prevents an editor from confidently identifying what a patient or buyer would receive. A third-party exporter can repeat that mistake across dozens of pages.
The Super Vilitra record demonstrates the problem: its structured strength field and accompanying narrative do not agree. Original carton, insert and batch-specific documentation would be needed to resolve that discrepancy. An editor should report the supportable combined ingredients while leaving the precise strength unsettled; no foreign marketing text can normalize the product into an FDA-approved U.S. regimen.
Centurion-linked listings include a separately named Super Vilitra tablet containing both vardenafil and dapoxetine; it is not ordinary single-ingredient Vilitra. The vendor record is inconsistent about strength, with a 10 mg structured field and a narrative describing a vardenafil 20 mg/dapoxetine 60 mg combination. These conflicting details are not reliable enough to certify a specific combination dose without original packaging or a better primary record.
A conventional Vilitra tablet, a product with a “Professional” suffix and Super Vilitra should not be assigned the same ingredients, dosage form or FDA status from the brand stem. The second active ingredient introduces separate medication-interaction considerations. No U.S. approval for a foreign-market combination follows from vardenafil’s U.S. approval.
FDA product approval is tied to a distinct drug application and a defined product. The fact that vardenafil is approved in the United States does not approve Vilitra under its India-market branding or validate nonstandard advertised strengths.
Original Levitra branding was discontinued in the United States, while independently approved generics have their own records. Those generics, not a Vilitra online listing, are the relevant U.S. prescription products. Levitra history and generic approval context address those separate matters.
A marketing name such as “professional,” “soft” or “mouth dissolving” cannot be assumed to mean the FDA-approved 10 mg vardenafil ODT. U.S. ODT labels describe a particular orally disintegrating formulation with greater systemic exposure than film-coated 10 mg vardenafil; the two are not interchangeable.
Any foreign product claiming a new form must be evaluated independently for its ingredient, dose, manufacturing and marketing status. The ODT guide explains the precise formulation distinction rather than equating names.
If a medicine truly contains vardenafil, organic nitrates and riociguat are contraindicated. Clinicians also consider QT prolongation, certain antiarrhythmics, alpha-blockers, CYP3A4 inhibitors and cardiovascular circumstances. Uncertainty over an imported medicine’s true formulation increases risk.
People should not self-select a product based on the largest advertised strength, switch between PDE5 agents or assume a marketing promise of stronger effects. The nitrate warning and U.S. dosing context provide the approved-product perspective.
An original Vilitra pack and insert should show the exact product name, ingredients, strength, form, batch details, manufacturer and marketer. Those fields should agree with a credible record from the intended market. An exporter’s repeated product-card text is not enough when the source fields contradict one another.
If the identity is still unclear, publish only the independently supportable corporate association and explicitly mark the specific SKU as unresolved. This page is not an ordering or import guide and does not endorse a supplier.
Patients considering vardenafil should seek professional assessment and use a licensed U.S. pharmacy for a valid prescription. The pharmacist can identify FDA-approved products, labeled strengths and current local availability rather than trying to match a foreign marketing trade name.
For a lawful dispensing workflow, see the buying guide and the pharmacy stock-check guide. A valid prescription remains necessary regardless of the trade name found in searches.
Centurion-linked listings associate ordinary Vilitra with vardenafil; the separately named Super Vilitra is listed as vardenafil plus dapoxetine. The available numerical fields for that combination conflict and require separate pack-level verification.
The company lists Vilitra products, but each package’s manufacturer, marketer and exporter roles require product-specific evidence.
Listings include 10 mg and 20 mg tablet descriptions, but inconsistencies affect some other catalog entries; verify each original pack before asserting a strength.
Some Centurion catalog fields conflict. Without corrected primary documentation, that SKU should not be treated as unambiguously verified.
No such equivalence can be assumed. The FDA-approved 10 mg ODT has separate labeling and substitution restrictions.
A foreign-market brand listing does not establish a product-specific FDA-approved application.
Do not assume a lawful routine import pathway for an unapproved foreign product; use legitimate U.S. prescribing and pharmacy channels.
That claim is not established by a marketing listing, and nonstandard or uncertain strengths should not guide patient dosing.